Clinical trials
Observational Pleural Effusion, Malignant trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
38 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2004 | 1 |
| 2005 | 1 |
| 2006 | 1 |
| 2007 | 2 |
| 2010 | 1 |
| 2012 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2016 | 3 |
| 2017 | 2 |
| 2018 | 4 |
| 2020 | 4 |
| 2021 | 2 |
| 2022 | 4 |
| 2023 | 3 |
| 2024 | 4 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 18 |
| Unknown status | 11 |
| Not yet recruiting | 3 |
| Recruiting | 2 |
| Withdrawn | 2 |
| Enrolling by invitation | 1 |
| Terminated | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Naestved Hospital | 3 |
| The University of Hong Kong | 2 |
| Travera Inc | 2 |
| University of Oxford | 2 |
| Assiut University | 1 |
| Attikon Hospital | 1 |
| Case Comprehensive Cancer Center | 1 |
| China-Japan Friendship Hospital | 1 |
| European Institute of Oncology | 1 |
| Fujirebio Diagnostics, Inc. | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pleural Effusion, Malignant | 38 |
| Lung Neoplasms | 10 |
| Pleural Effusion | 10 |
| Breast Neoplasms | 4 |
| Carcinoma, Non-Small-Cell Lung | 3 |
| Pleural Diseases | 3 |
| Anus Neoplasms | 2 |
| Appendiceal Neoplasms | 2 |
| Ascites | 2 |
| Carcinoma | 2 |
Trials
Showing 1 to 25 of 38. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.